Healthy Male Subjects Clinical Trial
Official title:
A Mass Balance Study of [14C] TAS-303 in Healthy Adult Male Subjects
Verified date | August 2023 |
Source | Taiho Pharmaceutical Co., Ltd. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
To evaluate the pharmacokinetics, mass balance recovery, metabolite profile and metabolite identification of [14C]TAS-303 following oral single dose
Status | Completed |
Enrollment | 6 |
Est. completion date | February 22, 2023 |
Est. primary completion date | November 3, 2022 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Male |
Age group | 18 Years to 40 Years |
Eligibility | Inclusion Criteria: 1. Healthy adult male subjects who provided written informed consent to participate in the study 2. Aged 18 years or older and younger than 40 years at the time of informed consent 3. Capable of oral intake. 4. Body weight of 50 kg or more and body mass index of 18.5 or more and less than 25.0 5. Had blood pressure, pulse rate, and body temperature meeting any of the following at screening: Systolic blood pressure: ?90 mmHg and ?139 mmHg, Diastolic blood pressure: ?40 mmHg and ?89 mmHg, Pulse rate: ?40 beats per minute (bpm) and ?99 bpm, Body temperature: ?35.0°C and ?37.4°C Exclusion Criteria: 1. Had current or previous hypersensitivity or allergy to drugs 2. Had current or previous drug abuse (including use of illicit drugs) or alcoholism 3. Had any concurrent disease (including symptoms and signs; however, diseases that do not affect evaluations in the study such as asymptomatic pollinosis and wart are excluded) 4. Received a radioisotope-labeled substance or subject to a large quantity of radiation exposure* within 12 months before the first dose of TAS-303. * A large quantity of radiation exposure includes continuous X-ray irradiation, computed tomography (CT) scan, gastric barium test, and positron emission tomography (PET) scan, excluding tests with low radiation exposure (e.g., chest, bone, or dental X-ray examination, or X-ray examination before boarding an airplane). 5. Occupationally exposed to radiation within a year before the first dose of TAS-303 (such as operators who are involved in nuclear power or radiation operations). |
Country | Name | City | State |
---|---|---|---|
Japan | A site selected by Taiho Pharmaceutical Co., Ltd. | Tokyo |
Lead Sponsor | Collaborator |
---|---|
Taiho Pharmaceutical Co., Ltd. |
Japan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Concentrations of total radioactivity in blood and plasma | Day1 to 8 and 10,12,14,16,18,20,22 | ||
Primary | Plasma TAS-303 concentrations | Day1 to 8 and 10,12,14,16,18,20,22 | ||
Primary | Maximum plasma concentration (Cmax) | Day1 to 8 and 10,12,14,16,18,20,22 | ||
Primary | Area under the plasma concentration versus time curve (AUC). | Day1 to 8 and 10,12,14,16,18,20,22 | ||
Primary | Elimination half life (T1/2) | Day1 to 8 and 10,12,14,16,18,20,22 | ||
Primary | Radioactivity cumulative excretion rate into urine | Day 1 to Day 22 | ||
Primary | Radioactivity cumulative excretion rate into feces. | Day 1 to Day 22 | ||
Primary | Radioactivity excretion and excretion rate,cumulative excretion, cumulative excretion rate in all excreta (urine and feces). | Day 1 to Day 22 | ||
Secondary | Adverse events | The number and incidence of Adverse events. | Day 1 to Day 29 | |
Secondary | Treatment-related adverse events | The number and incidence of Treatment-related adverse events. | Day 1 to Day 29 | |
Secondary | Number of Participants With Abnormal Laboratory Values | Screening period and Day -2, 8, 15, 22, 29 | ||
Secondary | Blood Pressure | Screening period and Day 1, 2, 8, 15, 22, 29 | ||
Secondary | Pulse rate | Screening period and Day 1, 8, 15, 22, 29 | ||
Secondary | Temperature | Screening period and Day 1, 2, 8, 15, 22, 29 | ||
Secondary | QTc interval | Screening period and Day 1, 8, 15, 22, 29 | ||
Secondary | Heart rate | Screening period and Day 1, 8, 15, 22, 29 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02901366 -
Mass Balance Study of FYU-981
|
Phase 2 | |
Not yet recruiting |
NCT01928563 -
Clinical Trial to Investigate the Pharmacokinetic Drug Interaction Between Udenafil and Dapoxetine
|
Phase 1 | |
Completed |
NCT05559554 -
A Study to Evaluate the PK Similarity of AK104 in Healthy Chinese Male Subjects
|
Phase 1 | |
Completed |
NCT04512872 -
A Phase I Study to Evaluate the Safety and Pharmacokinetics of CT-P41 and EU-approved Prolia in Healthy Male Subjects
|
Phase 1 | |
Active, not recruiting |
NCT06111196 -
Compare the Pharmacokinetics and Safety of BAT3306 Injection Versus KEYTRUDA® Administered in Healthy Male Subjects
|
Phase 1 | |
Completed |
NCT03317652 -
Effect of Sodium Nitroprusside on Cerebral Blood Flow
|
N/A | |
Completed |
NCT04655872 -
Mass Balance of Oral [14C]TPN171H in Healthy Male Subjects
|
Phase 1 | |
Active, not recruiting |
NCT02609711 -
Investigate a Interaction of Candesartan and Atorvastatin in Healthy Male Sugjects
|
Phase 1 | |
Withdrawn |
NCT02560363 -
A Study to Compare the Pharmacokinetics of Different Formulations of AZD9977 and the Influence of Food in Healthy Male Subjects
|
Phase 1 | |
Completed |
NCT01261260 -
Effect of Uridine on GABA and High Energy Phosphate Levels in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT05072028 -
Mass Balance and Biotransformation Study of [14C]DBPR108 in Human
|
Phase 1 | |
Completed |
NCT05446233 -
ADME Study of [14C] Antaitavir Hasophate in Healthy Male Subjects
|
Phase 1 | |
Completed |
NCT05275010 -
A Study in Healthy Male Subjects to Investigate the Comparability of Pharmacokinetics of the Fixed-Dose Combination of Pertuzumab and Trastuzumab Administered Subcutaneously Using a Handheld Syringe or Using the On-Body Delivery System
|
Phase 1 | |
Completed |
NCT04839744 -
A Comparative Study of TG103 Produced by Two Manufacturing Processes in Chinese Healthy Male Subjects
|
Phase 1 | |
Completed |
NCT05792917 -
Bioequivalence Study of Tafolecimab Injections in Chinese Healthy Male Volunteers
|
Phase 1 | |
Completed |
NCT03576651 -
A Study to Compare the Pharmacokinetics of JHL1149 and Bevacizumab (Avastin) in Healthy Male Volunteers
|
Phase 1 | |
Completed |
NCT04825431 -
Mass Balance Study of [14C] TAS-205 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT01819779 -
Clinical Trial to Assess the Pharmacokinetic Characteristics of Lodivixx Tab. 5/160mg in Healthy Male Subjects (N=60)
|
Phase 1 | |
Completed |
NCT05126784 -
AVT03 With Prolia in Healthy Male Subjects
|
Phase 1 | |
Completed |
NCT04850638 -
Drug Interaction Between SHR4640 Tablets and Furosemide Tablets in Healthy Volunteers (Single Center, Single Arm, Open, Self-control)
|
Phase 1 |